Introduction {#sec1-1}
============

Pilocarpine and mydriatics were the first ophthalmic sustained-release drug which was developed in an acrylate copolymer-based matrix for insertion into the conjunctival fornix.\[[@ref1]\] In the Western world in the 1970s, Ocusert (Alza), a sustained-release pilocarpine, was introduced.\[[@ref1]\] Different approaches have been proposed to deliver drugs into the eye. One of the main aims is to achieve therapeutic concentrations at the posterior pole. Successful ophthalmic therapy requires therapeutic concentrations of the active substance on the target site. Systemic applications may lead to sufficient concentrations at the retina; however, systemic side effects may develop, especially in the long-term use. Physicians and patients accept topical administration as a route for ocular medication. However, only 5% of the administered dose penetrate the eye which limits the therapeutic effect at the posterior pole.\[[@ref2]\] A major barrier to drug delivery after eye drop application is diffusion through the cornea.\[[@ref3][@ref4]\] However, a good number of low-molecular-weight substances can reach the aqueous humor through the transcorneal route by passive diffusion which follows Fick\'s law. The diffusion rate is conducted by a concentration gradient, specified by the hydrophilic or lipidic nature of the different layers of the cornea and the nature of the drugs administered (hydrophilic/lipophilic balance).\[[@ref5]\] Conjunctiva is a tissue with an endogenous transport machinery to allow penetration of active substances. It is considered an alternative route for ocular drug delivery with good absorption.\[[@ref6]\] The transscleral route consists of the injection of the drug into a periocular space (subconjunctival, sub-Tenon, peribulbar, posterior juxtascleral, and retrobulbar spaces).\[[@ref7]\] Transport barriers in the transscleral route have been classified as static and dynamic barriers.\[[@ref8]\] Knowing the permeability of the sclera, periocular may also offer an alternative route to potentiate drug delivery and tissue targeting.\[[@ref9][@ref10]\]

To overcome these routes limitations, numerous physicians have suggested intravitreal drug injections reach locally therapeutic levels with prolonged effective concentrations.

The eye is an ideal organ for sustained-release drug delivery implants. Posterior segment structures can be easily treated through an intravitreal drug delivery system or surgical implantation. The blood--retina barrier further helps to localize the intraocular concentration of the drug while decreasing the systemic absorption and side effects. The eye is also an immunologically privileged site, which limits the amount of inflammation related to the sustained-release device.\[[@ref1][@ref2][@ref11][@ref12]\]

Several different technologies exist for sustained-release drug delivery devices, including (1) biodegradable implants, (2) nonbiodegradable implants, (3) dendrimers, and (4) hydrogels.

The major benefits of intraocular implant are reduction of systemic side effects of the medication, decreased risk of repeated intravitreal injections, decreased total amount of drugs used for treatment, and localized therapeutic drug levels bypassing the blood--retina barrier.\[[@ref13][@ref14]\]

Method of Literature Search {#sec1-2}
===========================

A systematic literature review was performed using PubMed databases into two steps. The first step was oriented to classification of intraocular polymers implants focusing on their advantages and disadvantages. The second step was focused on the role of polymers therapy for intraocular pathology with clinical examples. The search strategy was not limited by year of publication.

Intraocular Polymers Implants {#sec1-3}
=============================

Biodegradable polymers {#sec2-1}
----------------------

Biodegradable polymers are widely used in the production of controlled drug delivery systems. These devices release the drug while the polymer is being degraded in the target site. With time, the device disappears avoiding the need of surgical removal. These materials have been used to prepare implants, liposomes, and injectable particles (nanoparticles and microparticles).

### Advantages {#sec3-1}

Do not require removalDesigned in various shapesCan be injected.

### Disadvantages {#sec3-2}

Shorter duration of actionRequire surgical implantation or injection.

### Clinical examples {#sec3-3}

Liposomes (verteporfin and ganciclovir)

Liposomes are biodegradable vesicles. They can be prepared with natural lipids as phospholipids. Hydrophilic can be encapsulated in the aqueous zone, and lipophilic active substances can be encapsulated in the lipid walls.

Liposomes have been dispersed in thermo-sensible poloxamers to save the activity of oligonucleotides and enhance their intracellular penetration.\[[@ref15]\]

The administration of liposomes by the intraocular route has been studied in several studies. Liposomes loaded with a prodrug of ganciclovir was used to treat cytomegalovirus (CMV) retinitis in rabbits.\[[@ref16]\] These vesicles have been loaded with oligonucleotides to protect them from nucleases.\[[@ref16]\] A liposomal formulation of verteporfin (Visudyne, Novartis Pharmaceuticals) is accepted for the treatment of age-related macular degeneration (AMD) and choroidal neovascularization (CNV). Liposomes of verteporfin are given to the patient by intravenous infusion, causing an occlusion of the targeted vessels after its activation through a nonthermal red laser applied to the retina.\[[@ref17][@ref18]\] Another example is Photrex (Miravant Medical Technologies) that contains rostaporfin.\[[@ref19]\]

Poly (lactic) acid and poly (lactic-co-glycolic) acid

They are biodegradable polymers and disappear from the injection site after drug delivery. These polymers have been employed to make implants, scleral plugs, pellets, discs, films, and rods.\[[@ref20]\] The implant is introduced into the eye through pars plana insertion.\[[@ref21]\] Ocular administration of micro- and nano-particles has been employed by intravitreal\[[@ref22]\] and periocular injections.\[[@ref23]\] Different drugs have been prepared with poly (lactic-co-glycolic) acid (PLGA) microparticles, such as, dexamethasone for uveitis, aciclovir for herpes infection, ganciclovir for CMV retinitis, neurotrophic factors for neuroprotection, 5-fluorouracil, adriamycin, and retinoic acid for proliferative retinopathy, and inhibitor of protein kinase C (PKC412) for CNV.\[[@ref24][@ref25]\] PLGA microspheres loaded with triamcinolone have also already been used in humans.\[[@ref26]\]

Dexamethasone sustained-release device (Ozurdex^®^)

The dexamethasone implant provides an initial shot of highly concentrated dexamethasone, followed by a gradual release over the following 3 months. Ozurdex is implemented in the treatment of posterior uveitis, diabetic macular edema (DME), and neovascular AMD. The clinical effects of Ozurdex for the treatment of macular edema may last up to 6 months. Several studies demonstrated that there were minimal cataract progression and 2% of study patients versus 1% of controls developed intraocular pressure (IOP) elevation of 10 mmHg at 3 months follow-up.\[[@ref1][@ref3][@ref27]\] An important advantage of Ozurdex is immediate effect of inflammation control in uveitis diseases or treatment of other retinal pathologic conditions with a gradual steady-state release without the need to explant the device. The major disadvantage is the shorter duration of action.

Fluocinolone acetonide implant (Iluvien)

Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant approved to treat DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in IOP. In analyses of two multinational trials in patients with DME previously treated with macular laser photocoagulation, fluocinolone acetonide intravitreal implant 0.2 μg/day was significantly more efficacious than sham injection in improving visual acuity.\[[@ref28]\] The implant is a linear tube 3 mm long and 0.37 mm in diameter that can be injected through a 25-gauge needle. The duration of action is between 18 and 36 months.\[[@ref1]\] The advantage of this drug delivery system is that it is a minimally invasive procedure, and it is biodegradable. This device has the same risk of glaucoma and cataract consistent with all intraocular corticosteroid implants.

Nonbiodegradable polymers {#sec2-2}
-------------------------

### Advantages {#sec3-4}

Controlled release for long duration.

### Disadvantages {#sec3-5}

Require surgical implant and removalNeed replacement of new implants.

### Clinical examples {#sec3-6}

Ganciclovir

The ganciclovir implant (Vitrasert) by Bausch and Lomb was the first intraocular sustained-release drug device approved for the treatment of CMV retinitis.\[[@ref29]\] It is useful if the patient is intolerant of systemic ganciclovir or if progression continues despite intravenous treatment.\[[@ref30]\] Their use was limited by serious side effects such as myelosuppression and renal toxicity, commonly encountered in acquired immunodeficiency syndrome patients.\[[@ref31]\] Intraocular administration of ganciclovir minimized these systemic side effects. The ganciclovir implant is composed of a nonbiodegradable polymer that released ganciclovir roughly 1 µg/h over a period of 8 months.\[[@ref1][@ref32]\] Uncommon complications related to the surgical implant of the device included retinal detachment, endophthalmitis, and vitreous hemorrhage.\[[@ref1][@ref3][@ref32][@ref33]\]

Fluocinolone acetonide

A fluocinolone acetonide implant (Retisert) by Bausch and Lomb has been approved by the Food and Drug Administration (FDA) for the treatment of chronic uveitis. This is the second nonbiodegradable intraocular polymer implant that needs surgical placement through the pars plana for the treatment of noninfectious posterior uveitis. The FDA-approved implant contains 0.59 mg of Retisert with a burst release of 0.6 µg/day. Over the next 30 days, the drug level gradually decreases to a steady level of 0.3 µg/day.\[[@ref1][@ref34][@ref35][@ref36]\] In a multicenter, randomized clinical trial of Retisert implants for the treatment of noninfectious posterior uveitis, the rate of recurrence was decreased from 51.4% before implant to 6.1% after implant.\[[@ref34]\] Visual acuity remained stable or improved in 87% of the patients studied. More than 50% of patients had pressure-lowering medication, and 5.8% required glaucoma surgery during the 34-week follow-up.\[[@ref34]\] At 3-year follow-up, implanted eyes showed significantly lowered the incidence of cystoid macular edema. The side effects included 92% of phakic patients requiring cataract surgery, increased IOP in 38% of patients requiring filtering procedure, and 2% requiring removal of the implant for glaucoma management.\[[@ref1][@ref3][@ref34]\] Rofagha *et al*. reported a spontaneous intraocular dissociation of a (Retisert) could happen years after placement, in the absence of trauma or other risk factors. Surgeons and patients must be aware of this potential complication.\[[@ref37]\]

Dendrimers {#sec2-3}
----------

Dendrimers are a new class of polymeric materials. They are "tree-like," nanostructured polymers that have been investigated in terms of ocular drug delivery. They are interesting systems for drug delivery due to their nanosize range, ability to have multiple surface groups that permit for targeting, and easy preparation and a good function.\[[@ref38]\] Ocular dendrimeric systems may enhance effective delivery of therapeutic agents to intraocular tissues, such as the retina or choroid, using noninvasive delivery methods. Dendrimers have been investigated for ophthalmic drug delivery since it offers a number of advantages as a carrier system. It has been reported that dendrimers were used for several purposes as a carrier system for ocular drug delivery, antioxidant delivery, peptide delivery, biomedical imaging, gene delivery, and genetic testing in ophthalmology.\[[@ref39]\]

### Advantages {#sec3-7}

Nanosize ranging from 1 to 100 nmCan encapsulate hydrophobic drug molecules into their internal cavities\[[@ref40]\]Targeting anywhere in the body is possible, due to the multiple functional groupsOn their surface which makes it potential to attach vector devices\[[@ref41][@ref42]\]Smaller generation dendrimers also have an enhancer effect on permeability since they have a better ability to move between cells.\[[@ref43]\]

### Disadvantages {#sec3-8}

Cytotoxicity is related to the chemistry of dendrimers. The interaction between surface cationic charge of dendrimers and negatively charged biological membranes is the main reason of toxicity\[[@ref44]\]It was shown that following repeated intravenous use or topical ocular application, dendrimers with cationic end groups are often toxic, whereas anionic dendrimers are not.

For this reason, it is necessary to modify the surface amine groups of these dendrimers with neutral or anionic moieties order to reduce toxicity.\[[@ref45][@ref46]\]

### Clinical examples {#sec3-9}

Pilocarpine nitrate and tropicamide

Several series of polyamidoamine (PAMAM) dendrimers was used to control ocular drug delivery of pilocarpine nitrate and tropicamide. A study of a "miotic activity test" on albino rabbits reported that these PAMAM formulations enhance pilocarpine nitrate bioavailability compared to the control and caused the prolonged reduction of IOP, indicating increased precorneal residence time.\[[@ref47]\]

Gatifloxacin

Marano *et al*.\[[@ref48]\] investigated dendrimeric polyguanidilyated translocators (DPTs), which are the potential ophthalmic carriers for gatifloxacin, a "fourth-generation fluoroquinolone." They approved for conjunctivitis treatment. The results have shown that the DPT forms stable gatifloxacin complexes and improves solubility, permeability, anti-MRSA activity, and *in vivo* delivery of gatifloxacin.

Vascular endothelial growth factor oligonucleotide

Of lipophilic amino acid (oligonucleotide \[ODN\]) dendrimers have been created with collagen scaffolds to improve better physical and mechanical properties and adhesion ability. Dendrimers-based approach was used for anti-vascular endothelial growth factor (VEGF)-ODN delivery. They were successfully tested in a rat model to treat CNV. The results concluded that dendrimer/ODN-1 complexes significantly suppressed VEGF expression in cell-level studies around 40%--60%. Examinations of injected rat eyes also showed that the complex injections caused no significant toxicity and damage.\[[@ref48]\]

Hydrogels {#sec2-4}
---------

The first appearance of the term "hydrogel" in the literature was in 1894.\[[@ref49]\] Hydrogels are polymers which have the characteristic to swell in water or aqueous solvent, and they keep the solvents in a swollen cross-linked gel for drug delivery. They can be nondegradable or degradable in application.\[[@ref50][@ref51]\] A thermo-sensitive hydrogel delivery system can encapsulate and release anti-VEGF agents.\[[@ref52]\] Due to its thermo-sensitive feature, the hydrogel can be injected in a liquid form to the vitreous cavity through a small gauge needle. When it is exposed to the body temperature, the solution rapidly becomes a solid gel that releases the encapsulated protein such as anti-VEGF agent. The current investigation showed that the thermosensitive hydrogel can encapsulate bevacizumab at a high rate, is nontoxic, and the characteristics of biodegradability and bioactivity appear to be a promising intravitreal injection carrier for bevacizumab delivery.\[[@ref53]\]

### Advantages {#sec3-10}

There are several advantages that make hydrogels an interesting drug delivery system the posterior segment.\[[@ref51][@ref54]\] The aqueous environment of hydrogels can protect cells and fragile drugs (such as peptides, proteins, oligonucleotides, and DNA). They serve as a good means of transport of nutrients to cells and products from cells. They can also be modified with cell adhesion ligands, and can change physical state (liquid to solid) in response to pH or temperature changes, and most importantly, they are highly biocompatible.

### Disadvantage {#sec3-11}

Among all, the hydrogel systems investigated over the years are temperature- and pH-responsive hydrogels. Kang Derwent and Mieler examined the potential toxicity of cross-linked thermo-sensitive hydrogels in a cell culture model.\[[@ref55]\] Poly (N-isopropylacrylamide) (PNIPAAm) hydrogel was examined. Pure NIPAAM (unpolymerized form), particularly acrylamide, has been shown to be toxic in the nervous system.\[[@ref56]\] However, there are some of the studies that have demonstrated that PNIPAAm (polymerized form) is not toxic.\[[@ref57][@ref58]\]

### Clinical examples {#sec3-12}

Poly (N-isopropylacrylamide) hydrogel

It is one of the famous thermo-sensitive materials which has a lower critical solution temperature (LCST) or transition temperature at \~32°C.\[[@ref59][@ref60]\] Below the LCST, the hydrogel is swollen, and above the LCST, the hydrogel will shrink. A change in physical state is rapid and reversible, which makes the thermo-sensitive hydrogel an attractive means of drug delivery. Hydrogel exists in a liquid gel-like phase; however, once the temperature is raised beyond its LCST, a solid gel is formed rapidly.

Conclusion {#sec1-4}
==========

Polymers implants are potential future sustained-release retinal drug delivery systems. Modern sustained-release technology will offer safety and long duration of action, and maintain continued bioactivity. Sustained-release technology may offer treatment for AMD, DME, proliferative diabetic retinopathy, retinal vascular occlusion, and uveitis.
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